Chromosomal microarray analysis offers a superior diagnostic yield over karyotyping for the evaluation of individuals with developmental disabilities. Many third-party payers, however, do not reimburse for microarray testing, citing a lack of evidence that patients benefit from testing.
METHODS:
A total of 46 298 postnatal patients were tested by chromosomal microarray analysis for a variety of indications, most commonly intellectual disability/developmental delay, congenital anomalies, dysmorphic features, and neurobehavioral problems. The frequency of detection of abnormalities associated with actionable clinical features was tallied, and the rate of physician response to a subset of abnormal tests results was monitored.
RESULTS: A total of 2088 diagnoses were made of more than 100 different disorders that have specific clinical features that warrant followup. The detection rate for these conditions using high-resolution whole-genome microarrays was 5.4%, which translates to 35% of all clinically significant abnormal test results identified in our laboratory. In a subset of cases monitored for physician response, appropriate clinical action was taken more than 90% of the time as a direct result of the microarray finding.
CONCLUSIONS:
The disorders diagnosed by chromosomal microarray analysis frequently have clinical features that need medical attention, and physicians respond to the diagnoses with specific clinical actions, thus arguing that microarray testing provides clinical utility for a significant number of patients tested. Pediatrics 2012;130:e1085-e1095 In recent years, chromosomal microarray analysis has had a large impact on the genetic evaluation of patients with intellectual disability/developmental delay, multiple congenital anomalies, and/ or autism spectrum disorder. For these clinical indications, microarray testing has a significantly higher diagnostic yield than conventional karyotype analysis. [1] [2] [3] This superior diagnostic utility has led to recommendations that genomic microarray analysis be the first-tier test over karyotyping for the genetic evaluation of patients with these indications. 1, 4 ,5 Yet, whereas karyotyping is routinely reimbursed by thirdparty payers, often microarray testing is not. 6-9 A major reason given for denial of coverage is that microarray testing is not medically useful. Many payers have indicated that there is an inadequate amount of published evidence that microarray testing offers clinical utility, 6-10 defined as a positive effect on patient management and/or clinical outcomes. 11 To assess the degree to which microarray testing provides medically useful information, we examined genomic copy number abnormalities detected in our laboratory to determine how often these abnormalities reveal diagnoses that warrant specific clinical follow-up. In a subset of cases, we tracked the clinical actions taken by referring physicians in response to the abnormal test result.
Our findings indicate that disorders diagnosed by microarray testing often include clinical features that need to be directly addressed and that referring physicians frequently initiate specific and appropriate clinical actions. 15 Abnormalities detected on all array platforms were tallied for this report. For the measurement of detection rate, only cases tested on oligonucleotide platforms were included in the calculations because the lowerresolution BAC-based platforms did not assay all of the genes reported here.
METHODS

RESULTS
Known Microdeletion and Microduplication Syndromes
On searching our database, we identified 1733 individuals who were found to have genomic copy number changes that encompassed regions corresponding to established microdeletion and microduplication syndromes that were selected for this study ( 
Hereditary Cancer Predisposition
A search of our database found 189 patients who have copy number changes detected by microarray analysis of genes associated with hereditary cancer risk (Table 2 ). Based on the indication for testing, only 16 patients had a known or suspected tumor risk before testing; for the remaining 92% of patients, the indications for testing were not related to cancer predisposition. In all cases, the referring physician was informed of the association Table 3 . d All of these patients have deletions of PTCH1 and are also listed in Table 2 . e Nine of these patients have deletions of GATA3 and are also listed in Table 3 . f Fourteen of these patients have a deletion of BMPR1A, and 1 of these 14 patients also has a deletion of PTEN. These cases are also listed in Table 2 . g Twenty-two of these patients have a deletion of FLI1 and are also listed in Table 3 . h Two of these patients have mosaicism for trisomy 12.
of the abnormality with cancer risk. It should also be noted that for 2 of the probands a parent was found to carry the same abnormality; therefore, risk was identified not just for the proband but also for other family members.
Letters that specifically addressed the risk to these relatives were sent to referring physicians.
The patient reported by Heald et al. 16 provides a dramatic example of how microarray analysis can benefit patients. Table 3 . We identified a number of patients who were at risk for more than one actionable phenotype as a result of a deletion that includes multiple dosage-sensitive genes. These cases included the following: (1) a patient with deletions of EDNRB and RB1, which put the patient at risk for hearing loss, Hirschsprung disease, and retinoblastoma; (2) 12 patients with deletions of MNX1 and KCNH2, thus putting them at risk for urologic, spinal, and anal abnormalities, as well as cardiac arrhythmia; (3) 9 patients with deletions of GATA3 and the DiGeorge 2 critical region, which put them at risk for hearing loss, renal anomalies, and cardiac abnormalities; (4) 4 patients with deletions of LHX4 and SERPINC1, putting them at risk for pituitary insufficiency as well as a clotting predisposition; and (5) 14 patients whose deletions encompassed the 10q22-q23 microdeletion critical region, as well as the gene BMPR1A. The 10q deletion 24 b Other genes were queried, but no pathogenic abnormalities were found in our database. These genes are MSH2, MLH1, SDHC, BRCA1, TSC1, PRKAR1A, and MEN1. c The GPC3 and SMAD4 cases are also included in Table 3 . d The 34 cases reported by Adams et al. 22 are included among these cases. e Fourteen of these patients have a deletion of the 10q22-q23 microdeletion critical region, and one of these 14 patients also has a deletion of PTEN. These patients are also listed in Table 1 . f These cases are also presented in Table 3 . g Duplications, rather than deletions, are associated with tumor risk. h These patients have the 9q22.3 deletion syndrome and are included in Table 1 . i One of these patients has the 10q22-q23 deletion syndrome and is included in Table 1 . j One of these patients also has a deletion of BMPR1A. Another example of a patient who benefited from the information given by microarray analysis was the case of a patient who was referred for microarray testing because of developmental delay, dysmorphic features, and multiple congenital anomalies. This 3-monthold infant was one of the patients noted previously with a deletion of 7q36 that included the MNX1 and KCNH2 genes. These findings not only provided a diagnosis of Currarino syndrome as a result of the MNX1 deletion (with its predisposition to urologic, spinal, and anal anomalies), but also susceptibility to long QT syndrome (owing to deletion of KCNH2). Following the array result, the patient had an electrocardiogram that showed an elongated QT interval, and prophylactic medical therapy was subsequently instituted.
Physician Responses to Microarray Results
Our data clearly show that microarray testing can identify individuals at risk for specific medical problems that warrant follow-up care. To determine whether these risks are in fact being addressed, for a subset of cases we queried referring physicians as to whether they took specific actions pertinent to the particular diagnosis made by microarray testing. Of the 122 inquiries made, we received 81 responses (from 46 different clinicians), which are tallied by gene in Table 4 . In 76 (94%) of the 81 cases, at least 1 of the appropriate clinical actions was taken by the referring physician after the receipt of the microarray result. Examples of these actions included an electrocardiogram and cardiology referral for those at risk for long QT syndrome; glucose monitoring and endocrine referral for those at increased risk of diabetes; renal ultrasound for those at risk for renal pathology; and platelet count monitoring for those at risk for thrombocytopenia.
Detection Rate of Clinically Actionable Abnormalities
A total of 46 298 microarray analyses were performed during the reporting period on postnatal proband samples, with nearly equal numbers tested on BAC and oligonucleotide array platforms (23 142 and 23 156, respectively). Of the 151 clinically actionable disorders reviewed, we detected pathogenic abnormalities for 118, resulting in a total of 2088 diagnoses. Of these cases, 1968 (94%) involved DNA segments that were shorter than 10 megabases and so would likely be missed by routine karyotyping. Our initial BAC arrays were targeted and did not probe the entire genome, and later BAC platforms did not provide the resolution necessary to detect all small copy number alterations that we currently address. Therefore, to obtain a more accurate estimate of our current detection rate of actionable conditions, we separately tallied cases tested on higher-resolution oligonucleotide arrays. The total number of diagnoses made using these arrays was 1259, giving a detection rate of 5.4%. We previously determined that our rate of detection of clinically significant alterations on oligonucleotide arrays is 15.4%. 17 Therefore, 35% of all pathogenic copy number changes found in our laboratory identify conditions for which specific clinical actions are warranted.
DISCUSSION
Karyotype analysis has long been used for the genetic evaluation of individuals with developmental abnormalities. The HHT, hereditary hemorrhagic telangiectasia. a SCN1A and SCN2A genes were both deleted in the cases. diagnostic yield of this testing for patients with developmental delay/ mental retardation varies in different studies, but the average is 4% to 5%. 18, 19 Karyotyping has been consistently reimbursed by third-party payers, but current concerns about health care costs are leading to higher expectations for the usefulness of laboratory tests, beyond simply providing a diagnosis. 20 It is increasingly expected that testing provide clinical utility, in the form of changes in patient management and improved clinical outcomes.
The first reported examples of the clinical utility of microarray testing were descriptions of deletions of tumor suppressor genes, which put the patients at a high risk of developing hereditary cancer syndromes. 16, 21, 22 Such patients benefit from awareness of tumor risk and appropriate clinical surveillance. [23] [24] [25] [26] Other studies showed that clinical actions were taken after abnormal microarray results, 27-30 although these studies were limited in scope and/or did not tie specific actions to diagnoses. These reports have not provided sufficient evidence to universally convince third-party payers that microarray testing is worthy of reimbursement.
The goal of our study was to examine the evidence for the clinical utility of chromosomal microarray analysis, which has already been demonstrated to have asuperiordiagnosticyieldoverkaryotyping for similar clinical indications. 1,4,5 Our approach was to identify specific diagnoses made by microarray testing, which are expected to lead to specific clinical actions and improved patient care. We identified more than 100 such disorders, ranging from complex syndromes involving multiple organ systems, to disorders with discrete problems that need obvious and specific medical follow-up. Admittedly, some of the patients may have displayed such problems before testing, but many of the disorders diagnosed have variable features that frequently are not evident or suspected. The test result thus serves to alert physicians to the possibility of these treatable problems.
We showed that these actionable diagnoses constitute a significant proportion (35%) of all pathogenic abnormalities detected by microarray analysis and that the detection rate of these disorders is greater than the overall detection rate of karyotype analysis for similar testing indications. We can expect the frequency of actionable diagnoses to increase in the future as we learn more about the clinical consequences of copy number abnormalities. Finally, we showed that physicians respond to abnormal microarray results with specific and appropriate clinical actions and noted several illustrative cases where the clinical outcome was optimized. Our findings, therefore, argue strongly that chromosome microarray analysis provides clinical utility for a significant number of tested patients.
CONCLUSIONS
Our data show that the diagnoses made by chromosomal microarray analysis frequently involve specific clinical features that may have been present but not apparent or were not yet manifest at the time of testing. Alerting physicians and families to these potential problems leads to optimal health management of patients, as demonstrated in the cases in which we queried the referring physicians. It is expected that anticipatory medical care of children and adults with developmental disabilities will lead to improved outcomes in terms of both general health and fulfillment of their developmental potential. Long-term follow-up studies could be performed to confirm this assumption, but in the meantime, our data show that microarray testing provides immediateclinical utilityforpatientsand such testing should be considered worthy of reimbursement by insurers. 
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